US-based Endologix, a developer of minimally invasive treatments for aortic disorders, has revealed positive clinical results for its Nellix technology, used for endovascular repair of abdominal aortic aneurysm.

The peer-reviewed article reported initial results from the international multicentre clinical trial, with successful aneurysm exclusion in all patients, and no late aneurysm, device-related adverse events or secondary procedures.

Lead author and scientific advisor of the article Carlos Donayre has said the Nellix device may now reduce the incidence of endoleaks, secondary interventions and the need for annual CT scan follow-up.

The article has been published in the February issue of the Journal of Vascular Surgery (JVS) and the study examined the initial and one year outcomes of 21 patients treated at four international centres.

Endologix president and CEO John McDermott said that the Nellix technology represents the next generation in endovascular repair of abdominal aortic aneurysms.

He also said that in addition to Nellix, Endologix’s Ventana fenestrated stent graft and AFX system also continue to advance on schedule.